NILOTINIB IN GIST FIRST LINE - BSG
British Sarcoma Group
Executive Office 35 Sandford Avenue Church Stretton Shropshire SY6 6BH Telephone 01694 722123
GIST
| Trial Name | NILOTINIB IN GIST FIRST LINE |
| Description | A randomized, open-label, multi-center phase III study to evaluate the efficacy and safety of nilotinib versus imatinib in adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST) |
| Reference | NCRN adopted 072 Sponsor: Novartis |
| Status / Sites | CLOSED BY SPONSOR |
| UK Chief Investigator Contact |
Soft Tissue Sarcoma - ADULT
Soft Tissue Sarcoma - PAEDIATRIC
Bone Sarcoma
GIST
You are viewing the text version of this site.
To view the full version please install the Adobe Flash Player and ensure your web browser has JavaScript enabled.
Need help? check the requirements page.
